Considering the relatively high 5-yr survival rate (76.9%) for bladder cancer (BC), its overall prevalence will probably continue to increase. Therefore, it is important to understand the effects of BC diagnosis and management, including psychological sequelae.
To assess the performance of a proton-specific knowledge based planning (KBPP) model in creation of robustly optimized intensity-modulated proton therapy (IMPT) plans for treatment of patients with prostate cancer.
Cisplatin-based neoadjuvant chemotherapy (NAC) has been shown to significantly improve survival in patients with clinically non-metastatic bladder cancer (cT2-4N0M0 MIBC).1–3 However, not every patient is likely to respond to NAC and is, therefore at risk for progression and delay of radical cystectomy (RC).4 Identification of patients who are unlikely to respond to NAC is of […]
Immune checkpoint inhibitors have revolutionised the care of multiple solid organ malignancies, including melanoma, lung and renal cell carcinoma. Unfortunately, the impact of this therapeutic class in metastatic castration-resistant prostate cancer (mCRPC) has been comparatively modest. Pivotal studies of checkpoint inhibitor monotherapy in mCRPC, including CA184-043,1 KEYNOTE-1992 and others,3 have shown modest response rates in the order […]
Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell-free DNA (cfDNA) has proven to be challenging.
Testicular germ cell tumours (TGCT) are the most frequent cancers in young men in developed countries and their incidence rate has doubled worldwide over the past 40 years. Early life exposures to pesticides are suspected to increase TGCT risk.
Clear cell renal cell carcinoma (ccRCC) is one of the most prevalent cancers. Thus, it is warranted to detect the status of metabolism-related genes (MRGs) and infiltrating immune cells in ccRCC progression for the prognosis of ccRCC.
Von Hippel-Lindau (VHL) disease is the main cause of inherited clear-cell renal cell carcinoma (ccRCC) and is caused by germline mutations in the VHL tumor suppressor gene. Bi-allelic VHL alterations lead to inactivation of pVHL, which plays a major role by downstream activation of the hypoxia inducible factor (HIF) pathway.
With improvements in systemic therapy, patients with metastatic malignancies are living longer; however, access to adequate palliative radiotherapy remains an issue. In this study, we aim to describe factors important in access to palliative radiotherapy in patients who received novel Androgen receptor-axis-targeted therapies (ARAT) and died of prostate cancer.
Evaluation of delivered dose to the dominant intraprostatic lesion (DIL) for moderately hypofractionated radiotherapy of prostate cancer by cone beam computed tomography (CBCT)-based dose accumulation and target coverage analysis.
